The Global Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 35.64 Bn in 2017, and is projected to exhibit a CAGR of 6.5% over the forecast period (2018 - 2026). Respiratory tract infection treatment market is expected to exhibit exponential growth over the forecast period due to rising pollution which in turn increasing the cases of respiratory tract infection. According to a National Center for Biotechnology Information (NCBI), 2013 in the U.S., 25% people are suffering from upper respiratory tract infection due to pollution and it is the most common reason for patients to visit the doctors. Various research organizations are developing novel lung therapies for the treatment of critically ill patients with acute respiratory distress syndrome (ARDS). For instance, scientists at Draper Laboratory are using unique manufacturing techniques and chip technology to precisely mimic blood vessels in the lungs, to treat patients with lung failure.
Moreover, asthma is one of the prime conditions leading to respiratory diseases, which are characterized by recurring attacks of panting and wheezing. The severity and frequency of asthma varies according to individual. According to the Center for Disease Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in the U.S. were suffering from asthma. Furthermore, 6.2 million people below the age of 18 years suffered from asthma.
Browse 25 Market Data Tables and 22 Figures spread through 157 Pages and in-depth TOC on "Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
To know the latest trends and insights related to respiratory tract infection treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/respiratory-tract-infection-treatment-market-2030
Strategies of vendors to implement new schemes and reimbursement rate for respiratory diseases attract the patients to undergo treatment, thereby propelling the respiratory tract infection treatment market growth. As per the data from GlaxoSmithKline (GSK) Australia, Trelegy Ellipta (single inhaler triple therapy for COPD) will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) for suitable adults in Australia suffering from moderate to severe chronic obstructive pulmonary diseases (COPD) from June 1, 2018. Increasing approval of new drugs by the Food and Drug Administration (FDA) is also expected to propel the overall market growth during the forecast period. For instance, in November 2017, US FDA approved Fasenra (Benralizumab) manufacture by AstraZeneca, a respiratory biologic for the patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Furthermore, in November 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) are looking forward to recommend the marketing authorization of Benralizumab. Benralizumab is also under regulatory review in Japan and several other countries.
Key Takeaways of the Respiratory Tract Infection Treatment Market:
- The global respiratory tract infection treatment market is expected to expand at a CAGR of 6.5% during the forecast period (2018 – 2026), owing to continuous technological advancements and increasing incidence of respiratory diseases
- Among drug class, non-steroidal anti-inflammatory drug (NSAIDS) segment is projected to grow at a higher pace over the forecast period, owing to easy availability of these drugs under Over the Counter (OTC) products at low price
- However, antibiotics will have the fastest growth rate in this market due to improved pharmacokinetics of these drugs to specifically target the respiratory tract infection and increasing prescription of antibiotics for curing respiratory tract infection
- Major players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.
Contact Us